Allogene Therapeutics Inc (ALLO) - Total Liabilities
Based on the latest financial reports, Allogene Therapeutics Inc (ALLO) has total liabilities worth $124.44 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Allogene Therapeutics Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Allogene Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Allogene Therapeutics Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Allogene Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Allogene Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Xinjiang Torch Gas Co Ltd
SHG:603080
|
China | CN¥719.37 Million |
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
USA | $94.61 Million |
|
BHG Group AB (publ)
ST:BHG
|
Sweden | Skr4.57 Billion |
|
Hangzhou Everfine Photo E Info
SHE:300306
|
China | CN¥81.67 Million |
|
Key Ware Electronics Co Ltd
TWO:5498
|
Taiwan | NT$1.75 Billion |
|
Scimee Sci &Tech Co Ltd
SHE:300425
|
China | CN¥2.05 Billion |
|
Chieftek Precision Co Ltd
TW:1597
|
Taiwan | NT$1.69 Billion |
|
Lux Industries Limited
NSE:LUXIND
|
India | Rs12.03 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Allogene Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ALLO stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Allogene Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Allogene Therapeutics Inc (2017–2024)
The table below shows the annual total liabilities of Allogene Therapeutics Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $126.53 Million | -3.12% |
| 2023-12-31 | $130.60 Million | -15.57% |
| 2022-12-31 | $154.70 Million | +23.14% |
| 2021-12-31 | $125.63 Million | -15.24% |
| 2020-12-31 | $148.21 Million | +66.94% |
| 2019-12-31 | $88.78 Million | +25.59% |
| 2018-12-31 | $70.69 Million | +3534450.00% |
| 2017-12-31 | $2.00K | -- |
About Allogene Therapeutics Inc
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell a… Read more